Metagenomi (MGX) Competitors

$1.38 +0.03 (+2.22%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$1.36 -0.02 (-1.45%)

As of 04:00 AM Eastern

MGX vs. MRNA, CRBU, ACB, DTIL, and TLSA

Should you buy Metagenomi stock or one of its competitors? MarketBeat compares Metagenomi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Metagenomi include Moderna (MRNA), Caribou Biosciences (CRBU), Aurora Cannabis (ACB), Precision BioSciences (DTIL), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry.

How does Metagenomi compare to Moderna?

Metagenomi (NASDAQ:MGX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

In the previous week, Moderna had 34 more articles in the media than Metagenomi. MarketBeat recorded 42 mentions for Moderna and 8 mentions for Metagenomi. Moderna's average media sentiment score of 0.62 beat Metagenomi's score of -0.19 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	21 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive

Metagenomi has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Metagenomi currently has a consensus price target of $9.00, indicating a potential upside of 552.17%. Moderna has a consensus price target of $35.73, indicating a potential downside of 29.13%. Given Metagenomi's stronger consensus rating and higher possible upside, equities research analysts plainly believe Metagenomi is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Metagenomi has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	2.06	-$87.87M	-$2.37	N/A
Moderna	$1.94B	10.29	-$2.82B	-$8.15	N/A

75.3% of Moderna shares are held by institutional investors. 17.8% of Metagenomi shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Moderna has a net margin of -143.55% compared to Metagenomi's net margin of -384.61%. Moderna's return on equity of -26.64% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Moderna	-143.55%	-26.64%	-19.32%

Summary

Moderna beats Metagenomi on 9 of the 17 factors compared between the two stocks.

How does Metagenomi compare to Caribou Biosciences?

Metagenomi (NASDAQ:MGX) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

In the previous week, Caribou Biosciences had 13 more articles in the media than Metagenomi. MarketBeat recorded 21 mentions for Caribou Biosciences and 8 mentions for Metagenomi. Caribou Biosciences' average media sentiment score of 0.09 beat Metagenomi's score of -0.19 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caribou Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Metagenomi has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.27, indicating that its stock price is 127% more volatile than the broader market.

Metagenomi presently has a consensus price target of $9.00, indicating a potential upside of 552.17%. Caribou Biosciences has a consensus price target of $8.67, indicating a potential upside of 310.74%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than Caribou Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Metagenomi has higher revenue and earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	2.06	-$87.87M	-$2.37	N/A
Caribou Biosciences	$11.16M	18.75	-$148.12M	-$1.42	N/A

77.5% of Caribou Biosciences shares are held by institutional investors. 17.8% of Metagenomi shares are held by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Metagenomi has a net margin of -384.61% compared to Caribou Biosciences' net margin of -1,189.14%. Metagenomi's return on equity of -51.23% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%

Summary

Metagenomi beats Caribou Biosciences on 10 of the 16 factors compared between the two stocks.

How does Metagenomi compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

47.6% of Aurora Cannabis shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by insiders. Comparatively, 17.8% of Metagenomi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aurora Cannabis has higher revenue and earnings than Metagenomi. Aurora Cannabis is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$246.72M	0.80	$1.63M	-$1.08	N/A
Metagenomi	$25.21M	2.06	-$87.87M	-$2.37	N/A

Aurora Cannabis has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Metagenomi has a consensus price target of $9.00, indicating a potential upside of 552.17%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Aurora Cannabis has a net margin of -23.46% compared to Metagenomi's net margin of -384.61%. Aurora Cannabis' return on equity of -0.04% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-23.46%	-0.04%	-0.03%
Metagenomi	-384.61%	-51.23%	-36.62%

In the previous week, Metagenomi had 5 more articles in the media than Aurora Cannabis. MarketBeat recorded 8 mentions for Metagenomi and 3 mentions for Aurora Cannabis. Aurora Cannabis' average media sentiment score of 0.96 beat Metagenomi's score of -0.19 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurora Cannabis	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Metagenomi	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Metagenomi beats Aurora Cannabis on 9 of the 17 factors compared between the two stocks.

How does Metagenomi compare to Precision BioSciences?

Precision BioSciences (NASDAQ:DTIL) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Precision BioSciences has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Precision BioSciences has higher revenue and earnings than Metagenomi. Precision BioSciences is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	6.28	-$45.72M	-$3.67	N/A
Metagenomi	$25.21M	2.06	-$87.87M	-$2.37	N/A

38.0% of Precision BioSciences shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by insiders. Comparatively, 17.8% of Metagenomi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Precision BioSciences presently has a consensus price target of $36.33, indicating a potential upside of 335.65%. Metagenomi has a consensus price target of $9.00, indicating a potential upside of 552.17%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than Precision BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Precision BioSciences has a net margin of -96.73% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-85.37%	-37.34%
Metagenomi	-384.61%	-51.23%	-36.62%

In the previous week, Metagenomi had 6 more articles in the media than Precision BioSciences. MarketBeat recorded 8 mentions for Metagenomi and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 0.94 beat Metagenomi's score of -0.19 indicating that Precision BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Metagenomi	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Metagenomi beats Precision BioSciences on 9 of the 16 factors compared between the two stocks.

How does Metagenomi compare to Tiziana Life Sciences?

Tiziana Life Sciences (NASDAQ:TLSA) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Tiziana Life Sciences has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Tiziana Life Sciences has higher earnings, but lower revenue than Metagenomi.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Metagenomi	$25.21M	2.06	-$87.87M	-$2.37	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Tiziana Life Sciences has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Tiziana Life Sciences' return on equity of 0.00% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Metagenomi	-384.61%	-51.23%	-36.62%

In the previous week, Metagenomi had 7 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 8 mentions for Metagenomi and 1 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.89 beat Metagenomi's score of -0.19 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Tiziana Life Sciences	Very Positive
Metagenomi	Neutral

Summary

Metagenomi beats Tiziana Life Sciences on 7 of the 12 factors compared between the two stocks.

Get Metagenomi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGX vs. The Competition

Export

Metric	Metagenomi	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$50.82M	$3.04B	$6.30B	$12.20B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-0.60	18.86	21.00	25.58
Price / Sales	2.06	289.31	554.55	78.84
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	0.38	4.35	9.75	6.66
Net Income	-$87.87M	$72.19M	$3.55B	$333.63M
7 Day Performance	-2.82%	-1.05%	-0.53%	-0.11%
1 Month Performance	-3.50%	-0.02%	1.20%	3.94%
1 Year Performance	-8.00%	46.31%	41.22%	36.07%

Metagenomi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGX Metagenomi	2.8306 of 5 stars	$1.38 +2.2%	$9.00 +552.2%	-13.8%	$50.82M	$25.21M	N/A	236	Earnings Report Analyst Forecast Gap Down
MRNA Moderna	1.4631 of 5 stars	$53.70 +1.6%	$35.73 -33.5%	+97.8%	$21.26B	$1.94B	N/A	4,700	Trending News
CRBU Caribou Biosciences	2.4876 of 5 stars	$2.03 -0.1%	$8.67 +327.4%	+169.5%	$200.84M	$11.16M	N/A	100	Trending News Earnings Report Analyst Forecast Analyst Revision
ACB Aurora Cannabis	0.9629 of 5 stars	$3.40 -0.7%	N/A	-35.3%	$200.68M	$246.72M	N/A	1,130
DTIL Precision BioSciences	2.2357 of 5 stars	$7.63 -3.0%	$36.33 +376.4%	+62.3%	$196.96M	$34.26M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Metagenomi (MGX) Competitors

MGX vs. MRNA, CRBU, ACB, DTIL, and TLSA

How does Metagenomi compare to Moderna?

Summary

How does Metagenomi compare to Caribou Biosciences?

Summary

How does Metagenomi compare to Aurora Cannabis?

Summary

How does Metagenomi compare to Precision BioSciences?

Summary

How does Metagenomi compare to Tiziana Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX vs. The Competition

Metagenomi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Metagenomi (MGX) Competitors

MGX vs. MRNA, CRBU, ACB, DTIL, and TLSA

How does Metagenomi compare to Moderna?

Does the media refer more to MGX or MRNA?

Which has more risk & volatility, MGX or MRNA?

Do analysts rate MGX or MRNA?

Which has better valuation & earnings, MGX or MRNA?

Do institutionals and insiders believe in MGX or MRNA?

Is MGX or MRNA more profitable?

Summary

How does Metagenomi compare to Caribou Biosciences?

Does the media refer more to MGX or CRBU?

Which has more volatility and risk, MGX or CRBU?

Do analysts rate MGX or CRBU?

Which has preferable valuation and earnings, MGX or CRBU?

Do institutionals and insiders have more ownership in MGX or CRBU?

Is MGX or CRBU more profitable?

Summary

How does Metagenomi compare to Aurora Cannabis?

Do institutionals & insiders have more ownership in ACB or MGX?

Which has preferable earnings & valuation, ACB or MGX?

Which has more risk & volatility, ACB or MGX?

Do analysts prefer ACB or MGX?

Is ACB or MGX more profitable?

Does the media favor ACB or MGX?

Summary

How does Metagenomi compare to Precision BioSciences?

Which has more risk & volatility, DTIL or MGX?

Which has preferable earnings & valuation, DTIL or MGX?

Do institutionals & insiders have more ownership in DTIL or MGX?

Do analysts prefer DTIL or MGX?

Is DTIL or MGX more profitable?

Does the media favor DTIL or MGX?

Summary

How does Metagenomi compare to Tiziana Life Sciences?

Which has more volatility & risk, TLSA or MGX?

Which has better earnings and valuation, TLSA or MGX?

Do analysts rate TLSA or MGX?

Is TLSA or MGX more profitable?

Does the media refer more to TLSA or MGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX vs. The Competition

Metagenomi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools